13F Holdings
中文EN

KZIA KAZIA THERAPEUTICS LTD IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1075880 · Reporting currency AUD · Fiscal year ends 06/30

Financial factors as of 2018-06-30 (FY2018), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-52.2%
TTM net income YoY43.4%
TTM EPS YoY-447.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin-5,074.8%
FCF margin—
EBITDA margin—

Returns

ROE-27.1%
ROA-18.8%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets31.7%
Debt / equity0.00x
Current ratio2.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.43x
Accruals ratio8.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: AUD FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30FY20212021-06-30
Income statement
Revenue42,0002.31M0015.18M
R&D expense7.33M17.38M15.56M20.17M14.54M
SG&A expense8.72M13.56M8.58M5.11M7.02M
Pretax income-22.45M-27.05M-20.74M-25.38M-8.90M
Income tax-1.75M-271,000-271,000-368,000-484,000
Net income-20.70M-26.78M-20.46M-25.01M-8.42M
EPS (basic)-0.04-0.10-0.11-0.19-0.07
EPS (diluted)-0.04-0.10-0.11-0.19-0.07
Weighted avg. shares (diluted)547.94M263.68M184.28M132.47M117.67M
Balance sheet
Cash & equivalents4.34M1.66M5.24M7.36M27.59M
Receivables97,9113.90M3.90M91,00084,000
Current assets4.93M6.14M10.77M9.45M29.39M
Intangibles1.09M15.40M17.27M19.14M21.01M
Total assets6.06M21.59M28.08M35.89M58.09M
Current liabilities14.05M25.80M7.57M6.73M8.33M
Short-term debt395,640634,0001.80M1.84M—
Total liabilities14.36M31.60M16.03M17.61M20.24M
Shareholders' equity-8.30M-10.02M12.05M18.27M37.85M
Cash flow statement
Operating cash flow-13.28M-9.58M-15.16M-22.76M-9.11M
Investing cash flow—00-2.37M—
Financing cash flow15.98M5.99M12.97M3.73M28.11M
Depreciation & amortization——1.87M1.87M1.26M
Stock-based compensation653,000533,0001.16M1.68M637,000
Dividends paid000——

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, AUD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.